Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 21Active not recruiting 5Terminated 2Not yet recruiting 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 4Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × enzalutamide × 30 days × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT03344211 2026-06-03

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

University of Southern California

Phase 2 Active not recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡